Read the latest and past features

Imaging tests such as X-rays, MRIs, and CT scans remain essential for diagnosing and managing psoriatic disease.

A major international study has examined how many people develop psoriasis worldwide and how this is likely to change over time.

As part of the BBC’s Scam Safe Week (22–28 November 2025), we’re sharing an important reminder for anyone living with long-term health conditions.

The International Psoriasis Council (IPC) has published an important systematic review on the way in which psoriasis affects children and their families.

Psoriasis is fundamentally an inflammatory disease which manifests itself in skin, joints and other body organs. There is a well-described link between psoriasis and cardiovascular disease, but the mechanism which connects skin inflammation to the cardiovascular system has, until now, been poorly understood.

People living with more severe psoriasis are at a greater risk of developing psoriatic arthritis (PsA), an inflammatory condition that affects the joints. Understanding this connection is important, as early and effective treatment for psoriasis may help reduce the risk of PsA.

Today, Wednesday, 29 October,  marks World Psoriasis Day 2025, where millions of people across the globe unite in recognition of the challenges faced by those living with psoriasis and psoriatic arthritis. As the official UK member of IFPA, we support this year's theme: "Psoriatic Disease and Comorbidities – Understanding the Domino Effect."​

Historically, most of the approaches to treating psoriasis have focused on inhibiting the actions of pro-inflammatory immune cells, i.e. the cells causing the inflammatory response.

This lively new edition explores the surprising role of fungal infections in psoriasis. Almost 1 in 6 patients in a recent study carried a hidden infection, often making their skin worse and harder to treat.

If you or someone you know is living with psoriasis or psoriatic arthritis, you’ve probably heard about biologic treatments, those breakthrough drugs that have changed the game for many managing these conditions. But what about biosimilars the “generic” versions of biologics? Are they the same? Different?